letermovir
Selected indexed studies
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. (N Engl J Med, 2017) [PMID:29211658]
- Letermovir. (, 2006) [PMID:30000008]
- Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. (JAMA, 2023) [PMID:37279999]
_Worker-drafted node — pending editorial review._
Connections
letermovir is a side effect of
Sources
- Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. (2023) pubmed
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. (2017) pubmed
- Letermovir. (2006) pubmed
- Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2024) pubmed
- Letermovir. (2012) pubmed
- Letermovir for cytomegalovirus prophylaxis. (2019) pubmed
- Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients. (2024) pubmed
- Letermovir: First Global Approval. (2018) pubmed
- Letermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients. (2025) pubmed
- The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies. (2024) pubmed